Alkermes plc.ALKSEarnings & Financial Report
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.
Revenue
$378.1M
Gross Profit
$315.0M
Operating Profit
$104.8M
Net Profit
$92.4M
Gross Margin
83.3%
Operating Margin
27.7%
Net Margin
24.4%
YoY Growth
-0.7%
EPS
$0.55
Alkermes plc. Q3 FY2024 Financial Summary
Alkermes plc. reported revenue of $378.1M (down 0.7% YoY) for Q3 FY2024, with a net profit of $92.4M (up 93.4% YoY) (24.4% margin). Cost of goods sold was $63.1M, operating expenses totaled $210.3M.
Key Financial Metrics
| Total Revenue | $378.1M |
|---|---|
| Net Profit | $92.4M |
| Gross Margin | 83.3% |
| Operating Margin | 27.7% |
| Report Period | Q3 FY2024 |
Revenue Breakdown
Alkermes plc. Q3 FY2024 revenue of $378.1M breaks down across 5 segments, led by Vivitrol at $113.7M (30.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Vivitrol | $113.7M | 30.1% |
| Royalty | $89.2M | 23.6% |
| Aristada And Aristada Initio | $84.7M | 22.4% |
| LYBALVI | $74.7M | 19.8% |
| Manufacturing Revenue | $15.9M | 4.2% |
Alkermes plc. Revenue by Segment — Quarterly Trend
Alkermes plc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Vivitrol and Royalty) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Vivitrol | $124.1M | — | $121.7M | $101.0M |
| Royalty | $65.7M | $68.0M | $66.9M | — |
| Aristada And Aristada Initio | $97.2M | — | $101.3M | $73.5M |
| LYBALVI | $94.1M | — | $84.3M | — |
| Manufacturing Revenue | $3.3M | $8.8M | $16.6M | $17.3M |
Alkermes plc. Annual Revenue by Year
Alkermes plc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.5B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.5B |
| 2024 | $1.6B |
| 2023 | $1.7B |
| 2022 | $1.1B |
Alkermes plc. Quarterly Revenue & Net Profit History
Alkermes plc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $384.5M | -10.6% | $49.3M | 12.8% |
| Q3 FY2025 | $394.2M | +4.2% | $82.8M | 21.0% |
| Q2 FY2025 | $390.7M | -2.1% | $87.1M | 22.3% |
| Q1 FY2025 | $306.5M | -12.5% | $22.5M | 7.3% |
| Q4 FY2024 | $430.0M | +13.9% | $146.5M | 34.1% |
| Q3 FY2024 | $378.1M | -0.7% | $92.4M | 24.4% |
| Q2 FY2024 | $399.1M | -35.4% | $91.4M | 22.9% |
| Q1 FY2024 | $350.4M | +21.8% | $36.8M | 10.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $350.4M | $399.1M | $378.1M | $430.0M | $306.5M | $390.7M | $394.2M | $384.5M |
| YoY Growth | 21.8% | -35.4% | -0.7% | 13.9% | -12.5% | -2.1% | 4.2% | -10.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.12B | $2.21B | $2.16B | $2.06B | $2.08B | $2.25B | $2.33B | $2.49B |
| Liabilities | $869.1M | $922.8M | $863.2M | $590.6M | $570.4M | $628.2M | $596.1M | $667.7M |
| Equity | $1.25B | $1.28B | $1.29B | $1.46B | $1.51B | $1.62B | $1.73B | $1.82B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $21.1M | $146.0M | $81.6M | $190.4M | $98.8M | $150.2M | $101.7M | $170.1M |